Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

Meanwhile, Aurinia reported improved outcomes in lupus nephritis therapy during the European Alliance of Associations for Rheumatology (EULAR) 2024, showing that a treatment regimen including LUPKYNIS ...

particularly those without established risk factors such as concomitant lupus nephritis, aPL positivity, and active serological and clinical disease status (4, 11). In line with this, the European ...

Approximately one-third of participants had a history of lupus nephritis (n=15). Despite starting with four ... and all but five participants in the Persistent group also met 2019 EULAR/ACR criteria.

Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...

REPEAT kidney biopsies may play an essential role in managing lupus nephritis, particularly for patients whose disease ...

Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...